Chun Shing Kwok1, Yoon Kong Loke. 1. School of Medicine, Health Policy and Practice, University of East Anglia, Norwich, UK.
Abstract
BACKGROUND: There is considerable debate regarding the negative impact of concomitant proton pump inhibitor (PPI) therapy on the antiplatelet efficacy of clopidogrel. AIM: The aim of this study was to perform a systematic review of studies that have evaluated the platelet function of patients receiving clopidogrel alone compared with those receiving both clopidogrel and PPIs. METHODS: We searched MEDLINE, EMBASE and the Cochrane Controlled Trials Register in February 2011 for randomized and non-randomized studies that reported platelet function results in patients taking clopidogrel, with or without PPIs. RESULTS: Our review included 19 studies (13 trials and 6 observational studies) involving 4693 patients. There was considerable heterogeneity in the study designs, patient characteristics, laboratory tests of platelet function, and drug exposure (dose and duration of PPI and clopidogrel). There was some evidence against omeprazole, with five of nine studies demonstrating a significant interaction with clopidogrel. The available platelet function data on esomeprazole (six studies) or pantoprazole (six studies) did not demonstrate a significant interaction. Of the six studies that statistically analysed platelet function data with omeprazole compared with pantoprazole, three showed a significantly greater interaction between omeprazole and clopidogrel, whereas three studies with limited sample sizes were unable to find a significant difference in the effects of omeprazole and pantoprazole. CONCLUSION: Platelet function studies do not demonstrate a clear or consistent interaction between clopidogrel and PPIs. These studies are difficult to interpret given the lack of information on drug exposure (dose and duration), variation in laboratory methodology and lack of genetic information. Consequently, platelet function data are of uncertain clinical relevance in determining the risk of an adverse cardiovascular interaction between PPIs and clopidogrel. Clinicians should continue to clinically assess the gastrointestinal risk of the patients and make their prescribing decision for PPIs based on any anticipated benefits in reducing risk of peptic ulcers and gastrointestinal haemorrhage.
BACKGROUND: There is considerable debate regarding the negative impact of concomitant proton pump inhibitor (PPI) therapy on the antiplatelet efficacy of clopidogrel. AIM: The aim of this study was to perform a systematic review of studies that have evaluated the platelet function of patients receiving clopidogrel alone compared with those receiving both clopidogrel and PPIs. METHODS: We searched MEDLINE, EMBASE and the Cochrane Controlled Trials Register in February 2011 for randomized and non-randomized studies that reported platelet function results in patients taking clopidogrel, with or without PPIs. RESULTS: Our review included 19 studies (13 trials and 6 observational studies) involving 4693 patients. There was considerable heterogeneity in the study designs, patient characteristics, laboratory tests of platelet function, and drug exposure (dose and duration of PPI and clopidogrel). There was some evidence against omeprazole, with five of nine studies demonstrating a significant interaction with clopidogrel. The available platelet function data on esomeprazole (six studies) or pantoprazole (six studies) did not demonstrate a significant interaction. Of the six studies that statistically analysed platelet function data with omeprazole compared with pantoprazole, three showed a significantly greater interaction between omeprazole and clopidogrel, whereas three studies with limited sample sizes were unable to find a significant difference in the effects of omeprazole and pantoprazole. CONCLUSION: Platelet function studies do not demonstrate a clear or consistent interaction between clopidogrel and PPIs. These studies are difficult to interpret given the lack of information on drug exposure (dose and duration), variation in laboratory methodology and lack of genetic information. Consequently, platelet function data are of uncertain clinical relevance in determining the risk of an adverse cardiovascular interaction between PPIs and clopidogrel. Clinicians should continue to clinically assess the gastrointestinal risk of the patients and make their prescribing decision for PPIs based on any anticipated benefits in reducing risk of peptic ulcers and gastrointestinal haemorrhage.
Authors: Thomas Gremmel; Sabine Steiner; Daniela Seidinger; Renate Koppensteiner; Simon Panzer; Christoph W Kopp Journal: J Cardiovasc Pharmacol Date: 2010-11 Impact factor: 3.105
Authors: Jesse Dawson; Terry Quinn; Mark Rafferty; Peter Higgins; Gautamanda Ray; Kennedy R Lees; Matthew R Walters Journal: Cardiovasc Ther Date: 2010-06-11 Impact factor: 3.023
Authors: Horst Neubauer; Andreas Engelhardt; Jan C Krüger; Sebastian Lask; Jan Börgel; Andreas Mügge; Heinz G Endres Journal: J Cardiovasc Pharmacol Date: 2010-07 Impact factor: 3.105
Authors: David N Juurlink; Tara Gomes; Dennis T Ko; Paul E Szmitko; Peter C Austin; Jack V Tu; David A Henry; Alex Kopp; Muhammad M Mamdani Journal: CMAJ Date: 2009-01-28 Impact factor: 8.262
Authors: Dirk Sibbing; Tanja Morath; Julia Stegherr; Siegmund Braun; Wolfgang Vogt; Martin Hadamitzky; Albert Schömig; Adnan Kastrati; Nicolas von Beckerath Journal: Thromb Haemost Date: 2009-04 Impact factor: 5.249
Authors: P Michael Ho; Thomas M Maddox; Li Wang; Stephan D Fihn; Robert L Jesse; Eric D Peterson; John S Rumsfeld Journal: JAMA Date: 2009-03-04 Impact factor: 56.272
Authors: B E Thames; J Lovvorn; M G Papich; R Wills; T Archer; A Mackin; J Thomason Journal: J Vet Pharmacol Ther Date: 2016-07-24 Impact factor: 1.786
Authors: José María Remes-Troche; Sergio Sobrino-Cossío; Julio César Soto-Pérez; Oscar Teramoto-Matsubara; Miguel Morales-Arámbula; Antonio Orozco-Gamiz; José Luis Tamayo de la Cuesta; Gualberto Mateos Journal: Clin Drug Investig Date: 2014-02 Impact factor: 2.859
Authors: Melissa Mejin; Wen Ni Tiong; Lana Yin Hui Lai; Lee Len Tiong; Adam Mohamad Bujang; Siaw San Hwang; Tiong Kiam Ong; Alan Yean Yip Fong Journal: Int J Clin Pharm Date: 2013-05-10
Authors: Dagmar F Hernandez-Suarez; Mariana R Botton; Stuart A Scott; Matthew I Tomey; Mario J Garcia; Jose Wiley; Pedro A Villablanca; Kyle Melin; Angel Lopez-Candales; Jessicca Y Renta; Jorge Duconge Journal: Pharmgenomics Pers Med Date: 2018-06-08